2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 400

Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis
Abstract Number: 2924

Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Abstract Number: 596

Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis
Abstract Number: 1792

Clinical-Biological and Pathological Spectrum and Outcome of IgA Vasculitis in Adults: A French Study
Abstract Number: 2777

Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients
Abstract Number: 2581

Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint
Abstract Number: 2900

Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Abstract Number: 686

Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey
Abstract Number: 2790

CMR with Quantitative T2 Mapping in Patients with Active SLE
Abstract Number: 902

Co-Management for Children with JIA: A Survey of Primary Care Providers Regarding Current Practices and Willingness to Provide Services
Abstract Number: 1053

Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis
Abstract Number: 1194

Cofilin-1 Is a ROS Sensor in Regulating the NLRP3 Inflammasome
Abstract Number: 2654

Cognitive Function in Systemic Lupus Erythematosus Patients with Past History of Neuropsychiatric Manifestations : A Longitudinal Study
Abstract Number: 2650

Cognitive Impairment in SLE and Non-Criterion Anti-Phospholipid Antibodies
Abstract Number: 1825

Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].